Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Payables (2021 - 2025)

Universe Pharmaceuticals' Payables history spans 5 years, with the latest figure at $7.1 billion for Q3 2025.

  • For Q3 2025, Payables rose 15.14% year-over-year to $7.1 billion; the TTM value through Sep 2025 reached $7.1 billion, up 15.14%, while the annual FY2025 figure was $7.1 billion, 15.14% up from the prior year.
  • Payables for Q3 2025 was $7.1 billion at Universe Pharmaceuticals, up from $6.2 billion in the prior quarter.
  • Across five years, Payables topped out at $7.1 billion in Q3 2025 and bottomed at $7.0 million in Q3 2022.
  • The 5-year median for Payables is $9.6 million (2021), against an average of $2.7 billion.
  • The largest annual shift saw Payables dropped 27.3% in 2022 before it surged 75679.98% in 2024.
  • A 5-year view of Payables shows it stood at $9.6 million in 2021, then decreased by 27.3% to $7.0 million in 2022, then grew by 16.87% to $8.2 million in 2023, then soared by 75679.98% to $6.2 billion in 2024, then rose by 15.14% to $7.1 billion in 2025.
  • Per Business Quant, the three most recent readings for UPC's Payables are $7.1 billion (Q3 2025), $6.2 billion (Q3 2024), and $8.2 million (Q3 2023).